Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Science / Health/  India first priority for AstraZeneca/Oxford vaccine delivery: Serum Institute
BackBack

India first priority for AstraZeneca/Oxford vaccine delivery: Serum Institute

The Oxford vaccine can be transported easily at normal refrigerator temperatures -- unlike some of the other candidates, which require extremely cold storage
  • The chief executive of the Serum Institute of India, Adar Poonawalla, said the manufacturer has already produced 40 million doses of the vaccine so far
  • Serum Institute chief executive officer Adar Poonawalla. (Mint)Premium
    Serum Institute chief executive officer Adar Poonawalla. (Mint)

    India will be given first priority for the delivery of the AstraZeneca/Oxford vaccine after its British developers claimed success following mass testing, the world's largest vaccine manufacturer by volume said Monday.

    The chief executive of the Serum Institute of India, Adar Poonawalla, said the manufacturer has already produced 40 million doses of the vaccine so far.

    "By January, we should have, you know, 100 million doses is minimum because we've already made 40 million doses," Poonawalla, whose father founded the vaccine manufacturer, told NDTV.

    Poonawalla said he expected that some 90 percent of Serum Institute's doses were to be sold to the Indian government at around 250 rupees (US$3.00).

    "Most of that 90 percent is what's going to go to the government of India and maybe 10 percent in the private market at the higher price (of 1,000 rupees)," he said.

    "We're hoping for this emergency use licence so that by the end of December, January we can start rolling out some (doses)."

    AstraZeneca and Oxford University said Monday that their drug had proved on average 70 percent effective at stopping the virus after trying it on 23,000 people.

    The Oxford drug can be transported easily at normal refrigerator temperatures -- unlike some of the other candidates, which require extremely cold storage.

    AstraZeneca said it planned to produce up to three billion doses of the vaccine in 2021 if it passes the remaining regulatory hurdles.

    The Serum Institute in August struck a deal with Gavi, the Vaccine Alliance, to produce up to 100 million COVID-19 doses of two different potential vaccines from AstraZeneca and US biotech company Novavax.

    Once the vaccines gain regulatory approval, the doses could be produced as early as the first half of 2021 for distribution to low- and middle-income countries, Gavi said.

    India's Health Minister Harsh Vardhan told India Today TV earlier Monday that he expected between 250-300 million Indians would be immunised by September next year.

    First in line would be health workers, other frontline workers including the police, paramilitary and those working in sanitisation, as well as people aged above 65, Vardhan added.

    Prime Minister Narendra Modi is expected to meet with state leaders on Tuesday for discussions about the distribution of the vaccine, local media reported.

    India is the second worst-infected nation after the United States with more than 9.1 million virus cases.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 24 Nov 2020, 05:35 AM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App